Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mass. vitamin settlement

This article was originally published in The Tan Sheet

Executive Summary

Fairness hearing slated for Aug. 28 in Cambridge state court on $19.6 mil. class action settlement of consumers' vitamin price-fixing claims against seven ingredient suppliers. Under the agreement tentatively approved April 22, settling defendants BASF, Daiichi Pharmaceutical, Eisai, Aventis Animal Nutrition, Hoffman-La Roche, Roche Vitamins and Takeda Chemical Industries deny liability. Settlement proceeds would be allocated to charitable groups providing food and nutrition programs in the state. Massachusetts consumers' indirect claims were not part of multi-state settlement involving the same defendants in October 2000 (1"The Tan Sheet" Oct. 16, 2000, p. 5)...

You may also be interested in...



Vitamin Price-Fixing $335 Mil. Settlement Reached For Indirect Purchasers

Twenty-four states and U.S. jurisdictions will use $145.6 mil. in proceeds from vitamin price-fixing settlements to fund health, education and scientific programs such as prenatal care and nutrition research.

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Topics

UsernamePublicRestriction

Register

PS094003

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel